Long-term therapy is often required for moderate-to-severe atopic dermatitis (AD). The purpose of this research was to report on the safety and efficacy of dupilumab therapy in people with moderate to severe Alzheimer’s disease for up to three years. This ongoing multicenter, open-label extension research looked at dupilumab therapy in people who had previously participated in dupilumab studies. Dupilumab 300 mg was given to patients once a week for a total of 148 weeks. The first goal was to ensure everyone’s safety. 347 of the 2677 patients that were recruited and treated made it to week 148. The average self-reported drug compliance rate was 98.2 per cent. The safety findings were consistent with previously published studies and the known safety profile of dupilumab. Nasopharyngitis, Alzheimer’s disease, upper respiratory tract infection, conjunctivitis, headache, oral herpes, and injection-site responses were among the most common adverse events. AD signs and symptoms improved with time, with a mean Eczema Area and Severity Index of 1.4 and a weekly Pruritus Numerical Rating Scale of 2.2 at week 148. There was no control arm; there were fewer patients at later time points, and the regimen was different from the authorised 300 mg every 2 weeks dosage.
These safety and effectiveness findings support the use of dupilumab as long-term, continuous therapy for individuals with moderate to severe Alzheimer’s disease.